Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT06056791 Recruiting - Cancer Clinical Trials

Study of INKmune in Patients With mCRPC (CaRe Prostate)

CaRe
Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.

NCT ID: NCT06055543 Recruiting - Cancer Clinical Trials

Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients

Start date: August 9, 2023
Phase: Phase 4
Study type: Interventional

This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition according to Global Leadership Initiative on Malnutrition (GLIM) criteria.

NCT ID: NCT06051695 Recruiting - Cancer Clinical Trials

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

EVEREST-2
Start date: April 3, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express MSLN and have lost HLA-A*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose of A2B694 that is safe for patients Phase 2: Does the recommended dose of A2B694 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen A2B694 Tmod CAR T cells at the assigned dose

NCT ID: NCT06050733 Recruiting - Cancer Clinical Trials

The Gut Microbiome and Immunotherapy Response in Solid Cancers

Start date: June 30, 2023
Phase:
Study type: Observational

The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.

NCT ID: NCT06048822 Recruiting - Cancer Clinical Trials

Enhancing Cancer Survivorship With Pickleball

Start date: September 11, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the feasibility and acceptability of a pickleball program for cancer survivors and their family members or friends. The program is designed to increase physical activity, improve wellness, and allow individuals to work together to learn and practice the sport.

NCT ID: NCT06043609 Recruiting - Cancer Clinical Trials

Outcome Evaluation After Fertility Preservation

Start date: September 21, 2023
Phase:
Study type: Observational

It is important to evaluate outcomes after different fertility preservation strategies. Therefore, this study aims to assess the outcomes after different fertility preservation strategies and identify any factors that may affect their reproductive outcome.

NCT ID: NCT06037681 Recruiting - Cancer Clinical Trials

Cannabis Use and Outcomes in Black and White Patients With Cancer

C4C
Start date: March 30, 2023
Phase:
Study type: Observational

The goal of the observational study is to learn how black and white patients with solid tumor cancer use cannabis, opioids and tobacco. The investigators are using momentary ecological assessment through a smart phone app and surveys to assess patient-reported pain and other symptoms as to inform clinical practice and guidelines for underrepresented populations.

NCT ID: NCT06037382 Recruiting - Depression Clinical Trials

Using a Smartphone App to Target Current Mental Health Symptoms of Anxiety and Depression

Start date: September 25, 2023
Phase: N/A
Study type: Interventional

This is a prevention intervention study that will examine the efficacy of a smartphone-based intervention in decreasing cancer risk by targeting mental health risk factors of anxiety and depression.

NCT ID: NCT06027021 Recruiting - Cancer Clinical Trials

Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET

ARTE-MISO
Start date: August 15, 2023
Phase:
Study type: Observational

Hypoxia is a known factor for resistance to radiotherapy in tumors. Response to transarterial radioembolization is known to be variable between different patients even if the same dose of radiation was delivered. In this study the investigators aim to quantify the hypoxia in the primary and secondary tumors of liver with 18F-FMISO PET before radioembolization and to prove any effect of the hypoxia, if present, on the dose that should be delivered to tumor to ensure treatment response.

NCT ID: NCT06023654 Recruiting - Cancer Clinical Trials

Identifying Circadian Rest-Activity Rhythm Disorders in Patients With Advanced Cancer

Start date: May 15, 2023
Phase:
Study type: Observational

Circadian rest-Activity Rhythm disorders (CARDs) are common in patients with cancer, particularly in advanced disease. CARDs are associated with increased symptoms, poorer quality of life, poorer response to anticancer treatments and shorter survival. The goal of this observational study is to see how common CARDs are in patients with advanced cancer and to characterise their rest and activity patterns in more detail. A recent study has outlined a standard way to assess and diagnose a CARD. This study aims to assess patients with advanced cancer for a CARD using a novel screening tool against this newly formed diagnostic criteria. Potentially modifiable risk factors will be considered along with associations between CARDs and symptoms, sleep preferences, sleep quality, daytime sleepiness, quality of life measures and predictors of survival.